Research · 2026-08-05
Peer-Reviewed Study Finds Kratom Extract Shows Complex Analgesic Profile Distinct From Buprenorphine in Dogs
Source: Frontiers in Pharmacology
Why it matters
Despite 10-20 million estimated kratom users in the U.S. seeking pain relief, rigorous preclinical analgesic data on kratom has been almost nonexistent. This blinded, randomized crossover study in dogs — using gold-standard quantitative sensory testing — provides the first structured comparison of kratom extract to buprenorphine across multiple pain modalities.
The big picture
Most kratom analgesic evidence comes from self-reports and surveys. Controlled animal models with validated pain measurement tools are essential before human clinical trials can be designed responsibly. The University of Florida team used quantitative sensory testing (QST), the same approach used in human neuropathic pain research, to measure how kratom affects different types of pain perception over time. This translational approach bridges the gap between pharmacology and clinical application.
Key findings
- Eight healthy beagle dogs received kratom extract (1 mg/kg mitragynine dose), buprenorphine (0.02 mg/kg IM), or placebo in a blinded, randomized, three-phase crossover design
- Buprenorphine showed broad-spectrum analgesic effects across all pain modalities tested
- Kratom showed a unique temporal profile and magnitude of effect that differed across modalities — it did not simply mirror buprenorphine's action
- Results suggest kratom modulates nociceptive pathways differently depending on the type of sensory stimulus
- Authors call for further investigation into specific alkaloids and active metabolites to explain the modality-specific effects observed
What they say
"These findings underscore the complex pharmacological profile of kratom, suggesting differential modulation of nociceptive pathways that warrants further investigation into its multiple alkaloids, active metabolites, and their specific contributions to the observed analgesic effect," the research team from the University of Florida wrote.
Bottom line
Kratom extract produces real but pharmacologically complex analgesic effects that differ from buprenorphine — findings that push toward the controlled human trials needed to evaluate it as a legitimate pain management option.